Dutch healthtech company Philips (PHG.AS) on Tuesday cut its 2026 forecast for comparable sales growth to 3% to 4.5% for 2026, below the roughly 4.5% expected previously.
The cautious outlook reflects mounting pressures from escalating U.S. tariffs and persistent weakness in China, where sales, representing roughly 10% of revenue, continue declining amid policy changes and weak hospital spending.
Chief executive Roy Jakobs said in December that the impact of U.S. tariffs was expected to "almost double" this year, pressuring margins despite ongoing cost cuts.
Philips reported fourth-quarter sales of 5.1 billion euros, with full-year sales of 17.8 billion euros, up 2%.
Adjusted EBITA (earnings before interest, tax, and amortisation) margin rose to 15.1% in Q4 and 12.3% for the year. The company said it achieved 800 million euros in cost savings in 2025 offsetting EUR 150-200 million in tariff costs.
Philips also said that it expects to generate free cash flow of between 1.3 billion and 1.5 billion euros.
The company proposed re-appointing Jakobs as CEO during its shareholder meeting in May.
关注我们
